News | Cardiovascular Ultrasound | November 14, 2019

FDA Clears AI-powered Cardiac Echo Analysis and Quantification by Ultromics

EchoGo Core AI automates cardiac analysis helping earlier detection of cardiovascular disease

EchoGo uses AI to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

EchoGo uses AI to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

EchoGo uses AI to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

November 14, 2019 — Ultromics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its artificial intelligence (AI) driven echocardiography image analysis system EchoGo Core.

The FDA approval is a major milestone for U.K.-based Ultromics and enables the business to make EchoGo available to clinicians and healthcare providers in the United States. EchoGo applies AI to automate the analysis and quantification of cardiac ultrasound heart scans.

EchoGo has been years in development, from the first trial being set-up in 2011 to Ultromics spinning out of the University of Oxford in 2017, and now achieving FDA clearance. The next stage of growth is commercializing the product and making it available to clinicians.

Traditionally, echocardiography has relied on the expert eye of clinicians, with years of experience, measuring the anatomical structures and identifying the disease, a potentially time-consuming and highly variable process. By automating the process and applying its AI analysis to look in greater detail at the scans, EchoGo enables clinicians to interpret echocardiograms efficiently and accurately and assists in their decision-making.

EchoGo uses AI to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

“Strain has shown to be very valuable in cardiovascular diagnostics and has been demonstrated in published studies to be linked with earlier detection of disease and improved patient outcomes," said Ross Upton, founder and CEO of Ultromics. "Ultromics’ will be the first to use artificial intelligence for automated strain analysis which is applicable to 60 million scans per year. Crucially, strain is also becoming reimbursable from January 2020 in the U.S. EchoGo allows clinicians across a wide range of experience to rapidly obtain accurate and repeatable calculations of strain parameters, assisting them in interpretation of echocardiograms”.

The company has more developments in the pipeline for 2020, including EchoGo Pro. It will be the first AI system able to predict cardiac disease from echocardiography. Ultromics also is planning to expand into other geographic regions, including Europe and Asia. 

Ultromics has partnerships with leading cardiology clinical centers in the United States and 30 National Health System (NHS) centers in the U.K. Through this, it is continuously optimizing its scanning algorithms by analyzing the archive of scans held by these centers. The pipeline of AI algorithms underpinning EchoGo was built using thousands of images from a carefully curated dataset, from one of the largest echo studies of its kind.

EchoGo is a vendor-neutral platform, which integrates into the medical imaging environment, seamlessly providing clinicians with results as part of their routine diagnostic workflow. 

For more information: visit www.ultromics.com

Related Content

An example of DiA'a automated ejection fraction AI software on the GE vScan POCUS system at RSNA 2019.

An example of DiA'a automated ejection fraction AI software on the GE vScan POCUS system at RSNA 2019.

News | Artificial Intelligence | May 26, 2020
May 26, 2020 — DiA Imaging Analysis, a provider of AI based ultrasound analysis solutions, said it received a governm
A list of all the abnormalities the AI model classifies. This illustration only shows three representative leads (DII, V1 and V6).Fig. This is Figure 1 from the Nature Communications article.

A list of all the abnormalities the AI model classifies. This illustration only shows three representative leads (DII, V1 and V6).Fig. This is Figure 1 from the Nature Communications article.

News | Artificial Intelligence | May 19, 2020
May 19, 2020 — Artificial inte...
TeraRecon will accelerate innovation in its advanced visualization and AI platforms for image-related decision support to clinical specialists

TeraRecon's End-to-End AI Ecosystem

News | Artificial Intelligence | March 04, 2020
March 4, 2020 — SymphonyAI Group, an operating group of lea
The FDA granted marketing authorization of the Caption Guidance software to Caption Health Inc. in February 2020. It uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

News | Artificial Intelligence | February 13, 2020
February 13, 2020 — The U.S.

GE Healthcare partnered with the AI developer Dia to provide an artificial intelligence algorithm to auto contour and calculate cardiac ejection fraction (EF). The app is now available on the GE Vscan pocket, point-of-care ultrasound (POCUS) system, as seen here displayed at RSNA 2019. Watch a VIDEO demo from RSNA.

Feature | Artificial Intelligence | February 11, 2020 | Sanjay Parekh, Ph.D. 
February 7, 2020 – At the 2019 Radiological Society...
A new technology for detecting low glucose levels via electrocardiogram (ECG) using a non-invasive wearable sensor, which with the latest artificial intelligence (AI) can detect hypoglycemic events from raw ECG signals has been made by researchers from the University of Warwick.

A new technology for detecting low glucose levels via electrocardiogram (ECG) using a non-invasive wearable sensor, which with the latest artificial intelligence (AI) can detect hypoglycemic events from raw ECG signals has been made by researchers from the University of Warwick.

 

News | Artificial Intelligence | January 13, 2020
A new technology for detecting low glucose levels via electrocardiogram (ECG) using a non-invasive wearable sensor,...
Videos | Artificial Intelligence | November 07, 2019
Piotr Slomka explains how his team at Cedars-Sinai is working on intelligent patient risk prediction algorithms...
AI Could Use EKG Data to Measure Patient's Overall Health Status

Image courtesy of iStock

News | Artificial Intelligence | August 29, 2019
In the near future, doctors may be able to apply artificial intelligence (AI) to electrocardiogram data in order to...